• Stéphane De Wit
  • Eric Florence
  • Linos Vandekerkhove
  • Jean-Christophe Goffard
  • Bernard Vandercam
  • Eric Van Wijngaerden
  • Michel Moutschen
  • Rémy Demeester
  • Patrick Lacor
  • Marc Delforge
  • Maartje van Frankenhuijsen
  • Paul Lacante

Objectives: This 5-year follow-up study aimed to assess clinical outcomes of HIV-1 infected adults treated with atazanavir (ATV) in clinical practice in Belgium, to describe patient profiles and characteristics, as well as treatment safety. Methods: A multicenter, non-interventional, non-comparative, retrospective cohort study was performed in HIV-1 positive adult patients treated with ATV between 2006 and 2012. Data were collected from 8 AIDS reference centers’ databases. All analyses were on-treatment. Sub-analyses were carried out in unboosted ATV treated patients and in females. The primary endpoint was defined as the time-to-treatment-discontinuation. Furthermore, virological suppression, immunological response, time to loss of virological response, reasons for ATV initiation, and discontinuation were also assessed. Results: 2264 ARV-naive and ARV-experienced patients (median age: 41 years) were included. Females and non-Caucasians were broadly represented (40 and 45%, respectively). The probability to remain on treatment was 0.78 (CI: 0.76; 0.78) for the first and 0.69 (CI: 0.66; 0.71) for the second year and was similar between males and females. Overall, 771 patients (34.1%) discontinued ATV over time, the median (Q1-Q3) time to discontinuation being 0.8 (0.3–1.5) year. In unboosted ATV-treated patients, results were comparable to the overall ATV population, except for a higher rate of discontinuation-over-time (45.1%). Conclusions: Clinical and safety data from this 5 year-cohort study show that the vast majority of patients remained on ATV treatment for the first and second years, overall as well as patients treated with unboosted ATV and females.

Original languageEnglish
Pages (from-to)143-150
Number of pages8
JournalActa Clinica Belgica
Issue number3
Early online date2 May 2018
Publication statusPublished - 4 May 2019

    Research areas

  • Atazanavir, Belgium, HIV, cohort

ID: 44887160